Results 91 to 100 of about 3,573 (200)

Waning light, waxing pain: The lunar cycle's association with migraine headache occurrence

Headache: The Journal of Head and Face Pain, Volume 66, Issue 3, Page 584-594, March 2026.
Plain Language Summary While migraine headaches can be hard to predict, some patients believe headaches are connected to the moon‘s phases. Our research showed that migraine attacks were 34% more likely to occur during the new moon than during the full moon.
Alexander Yoo, Brendan Keenan, Angeliki Vgontzas, Murray A. Mittleman, Suzanne M. Bertisch, Ron Anafi   +5 more
wiley   +1 more source

Additional effect of erenumab for patients with chronic migraine treated with onabotulinumtoxin A—real-world data from a preliminary cohort study

Frontiers in Neurology
BackgroundThis preliminary retrospective cohort study investigates the potential additive prophylactic effect of erenumab, a fully human monoclonal antibody that blocks the calcitonin gene-related peptide receptor, in combination with ongoing ...
Tristan Koelsche, Petyo Nikolov, Valeria Koska, Jens Ingwersen, Robin Jansen, Ercan Arat, Sven G. Meuth, Philipp Albrecht, Philipp Albrecht, John-Ih Lee   +9 more
doaj   +1 more source

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 3, Page 604-614, March 2026.
Abstract Objective This study assesses the 3‐month effectiveness of the calcitonin gene‐related peptide monoclonal antibody galcanezumab versus traditional oral migraine preventive medications. Background Studies comparing the effectiveness of calcitonin gene‐related peptide monoclonal antibodies versus traditional oral migraine preventive medications ...
Richard B. Lipton, Miguel J. A. Láinez, Zubair Ahmed, Carlos Vallarino, Diego Novick, Maurice Vincent, Lars Viktrup, Rebecca L. Robinson   +7 more
wiley   +1 more source

Competing treatments for migraine: a headache for decision-makers [PDF]

, 2023
BACKGROUND: Migraine is the world’s second most common disabling disorder, affecting 15% of UK adults and costing the UK over £1.5 billion per year.
Duncan, C, Madan, J, Matharu, M, Mistry, H, Naghdi, S, Underwood, M   +5 more
core  

Early clinical experience with a monoclonal antibody against the calcitonin gene-related peptide receptor in adolescents with migraine: A case series

Proceedings of Singapore Healthcare, 2020
Management of migraine in adolescents poses a great challenge, as many of the approved pharmacological migraine preventive agents have age restrictions.
Yi Jing Zhao, King-Hee Ho, Pei Shieen Wong   +2 more
doaj   +1 more source

Pharmacology of erenumab in human isolated coronary and meningeal arteries:Additional effect of gepants on top of a maximum effect of erenumab [PDF]

Background and Purpose: Multiple drugs targeting the calcitonin gene-related peptide (CGRP) receptor have been developed for migraine treatment. Here, the effect of the monoclonal antibody erenumab on CGRP-induced vasorelaxation was investigated in human
Bussiere, Jeanine, Dammers, Ruben, Danser, A. H.Jan, de Vries, Tessa, MaassenVanDenBrink, Antoinette, Rubio-Beltrán, Eloísa, Snellman, Josefin, van den Bogaerdt, Antoon   +7 more
core   +1 more source

Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 Months Following Initiation of Erenumab: A US Retrospective Real-World Analysis

Pain and Therapy
Introduction Erenumab-aooe is approved for the preventive treatment of migraine in adults. Recent publications have evaluated migraine medication use during the 6 months after starting erenumab, but longer-term follow-up data are limited.
Robert Urman, Nicole Princic, Fiston Vuvu, Leah B. Patel, Sam Oh, David Chandler, Nada Hindiyeh, Mark E. Bensink   +7 more
doaj   +1 more source

COMPARISON OF EFFICACY AND SAFETY OF NEWER DRUGS APPROVED FOR THE TREATMENT OF MIGRAINE DISORDER: A REVIEW [PDF]

, 2020
Migraine is a recurrent throbbing or pulsing headache with moderate to severe pain intensity. The pain is often one side of the head with nausea and weakness symptoms.
CHEW, TENG TENG, GOVINDARAJAN, ARULKUMARAN, KRISHNASAMY, KARTHIKAYINI, LAU, NATALIE JIA XIN, MEETOOA, BIBI MUNIIRAH UMMEH HAANI, NG, ELAINE, ONG, MICHELLA, ROSMAN, AIDIL NATASHA, SHANMUGASUNDARAM, AKILA, SHAPHERI, AINAA DIYANA, SIVANANDY, PALANISAMY, YEONG, MICHELLE ZI YIN   +11 more
core   +1 more source

Impact of CGRP monoclonal antibody treatment on blood pressure in patients with migraine:A systematic review and potential clinical implications [PDF]

Background: Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) or the CGRP-receptor have revolutionized the prevention of migraine. Despite their effectiveness, worries have surfaced regarding potential unwanted cardiovascular effects
Olsen, Michael H., Terwindt, Gisela M., Van Den Brink, Antoinette Maassen, van der Arend, Britt W.H., van Welie, Floor C., Versijpt, Jan   +5 more
core   +3 more sources

Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison

Journal of Comparative Effectiveness Research
Aim: To compare the efficacy of erenumab versus rimegepant as preventive treatment for patients with episodic and chronic migraine using an anchor-based matching-adjusted indirect comparison.
Ronan Mahon, Santosh Tiwari, Mirja Koch, Matias Ferraris, Keith A Betts, Yan Wang, Sophie Gao, Pascal Proot   +7 more
doaj   +1 more source